HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome versus severe preeclampsia: Onset at ≤28.0 weeks’ gestation (original) (raw)

Abstract

Our purpose was to determine whether the onset of the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome in women at ≤28.0 weeks' gestation is associated with an increased risk of adverse maternal and perinatal outcomes in comparison with the risk for women with severe preeclampsia but without the HELLP syndrome at a similar gestational age. STUDY DESIGN: Sixty-four patients with either the HELLP syndrome (n = 32) or severe preeclampsia but absent HELLP syndrome laboratory test results (n = 32), admitted at ≤28.0 weeks' gestation between July 1, 1992, and April 30, 1999, were studied. Maternal and perinatal outcomes were compared between the 2 groups. Statistical analysis was performed by the Student t test and the Fisher exact test. RESULTS: There were no significant differences between the 2 groups regarding African-American race (59% vs 75%), nulliparity (50% vs 56%), or the use of corticosteroids (59% vs 78%). There were no maternal deaths. One woman with the HELLP syndrome had a liver hematoma. The rate at which transfusion of blood products was required was significantly greater in women with the HELLP syndrome than in those with severe preeclampsia only (25% vs 3%; P < .05). There were no significant differences between the 2 groups with respect to eclampsia (16% vs 13%), abruptio placentae (6% vs 9%), disseminated intravascular coagulopathy (13% vs 0%), pulmonary edema (13% vs 6%), acute renal failure (3% vs 0%), pleural effusion (3% vs 3%), or ascites (6% vs 16%). No significant differences were found between the 2 groups with respect to neonatal death (11% vs 17%), respiratory distress syndrome (78% vs 86%), or composite neonatal morbidity. CONCLUSIONS: Except for the need for transfusion of blood products in women with the HELLP syndrome, onset at ≤28.0 weeks' gestation is not associated with an increased risk of adverse maternal or neonatal outcomes in comparison with the risk for women with severe preeclampsia but without the HELLP syndrome at a similar gestational age. (Am J Obstet Gynecol 2000;183:1475-9.)

Key takeaways

sparkles

AI

  1. Onset of HELLP syndrome at ≤28 weeks does not significantly increase adverse maternal/neonatal outcomes compared to severe preeclampsia.
  2. Transfusion requirement for HELLP syndrome patients was significantly higher at 25% versus 3% for severe preeclampsia.
  3. No maternal mortality occurred in either group during the study period.
  4. Both groups had similar rates of neonatal death and respiratory distress syndrome, around 11% and 78% respectively.
  5. The study reviews data from 64 women admitted between 1992-1999, focusing on severe preeclampsia and HELLP syndrome.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (17)

  1. The American College of Obstetricians and Gynecologists. Hy- pertension in pregnancy. Washington: The College; 1996. Tech- nical Bulletin No.: 219.
  2. Sibai BM, Taslimi M, Abdella TN, Brooks TF, Spinnato JA, An- derson GD. Maternal and perinatal outcome of conservative management of severe preeclampsia in midtrimester. Am J Ob- stet Gynecol 1985;152:32-7.
  3. Pattinson RC, Odendaal HJ, Du Toit R. Conservative manage- ment of severe proteinuric hypertension before 28 weeks' gesta- tion. S Afr Med J 1988;73:516-8.
  4. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gy- necol 1994;171:818-22.
  5. Sibai BM, Akl S, Fairlie F, Moretti M. A protocol for managing se- vere preeclampsia in the second trimester. Am J Obstet Gynecol 1990;163:733-8.
  6. Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Fried- man SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993;169:1000-6.
  7. Martin JN Jr, Rinehart BK, May WL, Magann EF, Terrone DA, Blake PG. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gy- necol 1999;180:1373-84.
  8. Audibert F, Friedman SA, Frangieh AY, Sibai BM. Clinical utility of strict diagnostic criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gy- necol 1996;175:460-4.
  9. Sibai BM. The HELLP syndrome (hemolysis, elevated liver en- zyme levels, and low platelets): much ado about nothing? Am J Obstet Gynecol 1990;162:311-6.
  10. Friedman SA, Schiff E, Lubarsky SL, Sibai BM. Expectant man- agement of severe preeclampsia remote from term. Clin Obstet Gynecol 1999;42:470-8.
  11. Martin JN Jr, Perry KG, Miles JF, Blake PG, Magann EF, Roberts WE, Martin RW. The interrelationship of eclampsia, HELLP syn- drome, and prematurity: cofactors for significant maternal and perinatal risk. Br J Obstet Gynaecol 1993;100:1095-100.
  12. Magann EF, Perry KG, Chauhan SP, Graves GR, Blake PG, Mar- tin JN Jr. Neonatal salvage by weeks' gestation in pregnancies complicated by HELLP syndrome. J Soc Gynecol Investig 1994; 1:206-9.
  13. Abramovici D, Friedman SA, Mercer BM, Audibert F, Kao L, Sibai BM. Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver en- zymes, and low platelet count) syndrome matter? Am J Obstet Gynecol 1999;180:221-5.
  14. Visser W, Wallenburg HCS. Temporising management of severe pre-eclampsia with and without the HELLP syndrome. Br J Ob- stet Gynaecol 1995;102:111-7.
  15. van Pampus MG, Wolf H, Westenberg SM, van der Post JAM, Bonsel GJ, Treffers PE. Maternal and perinatal outcome after ex- pectant management of the HELLP syndrome compared with preeclampsia with HELLP syndrome. Eur J Obstet Gynecol Re- prod Biol 1998;76:31-6.
  16. Magann EF, Bass D, Chauhan SP, Sullivan DL, Martin RW, Mar- tin JN Jr. Antepartum corticosteroids: disease stabilization in pa- tients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994;171: 1148-53.
  17. Tompkins MJ, Thiagarajah S. HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome: the benefit of cor- ticosteroids. Am J Obstet Gynecol 1999;181:304-9.